Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer-Reference-Cited by-同舟云学术

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Published:2014-02-03 Issue:6 Volume:30 Page:1007-1016
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

André Fabrice¹,Neven Patrick²,Marinsek Nina³,Zhang Jie⁴,Baladi Jean-Francois⁴,Degun Ravi³,Benelli Giancarlo⁵,Saletan Stephen⁴,Jerusalem Guy⁶

Affiliation:

1. Institut Gustave Roussy VillejuifFrance

2. University Hospitals Leuven LeuvenBelgium

3. Navigant Consulting Inc. LondonUK

4. Novartis Pharmaceuticals Corporation East Hanover, NJUSA

5. Novartis Farma S.p.A. Saronno/VAItaly

6. Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University LiègeBelgium

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2014.887002

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate;Clinical Drug Investigation;2023-08-18

2. Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-02-28

3. CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature;Current Oncology;2022-12-06

4. Terapia endocrina para el cáncer de MAMA RH+/HER2- avanzado/metastásico en Argentina;Oncología Clínica;2022-10-20

5. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT;Geburtshilfe und Frauenheilkunde;2022-07-12